1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Cutaneous Mastocytosis Global Clinical Trials Review, H1, 2014

Cutaneous Mastocytosis Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, “Cutaneous Mastocytosis Global Clinical Trials Review, H1, 2014" provides data on the Cutaneous Mastocytosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cutaneous Mastocytosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Cutaneous Mastocytosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Cutaneous Mastocytosis Global Clinical Trials Review, H1, 2014
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Cutaneous Mastocytosis 4
Report Guidance 4
Clinical Trials by Region 5
Clinical Trials and Average Enrollment by Country 6
Top Countries Contributing to Clinical Trials in Asia-Pacific 8
Top Five Countries Contributing to Clinical Trials in Europe 9
Top Countries Contributing to Clinical Trials in North America 10
Clinical Trials by G7 Countries: Proportion of Cutaneous Mastocytosis to Dermatology Clinical Trials 11
Clinical Trials by Phase in G7 Countries 12
Clinical Trials in G7 Countries by Trial Status 13
Clinical Trials by Phase 14
In Progress Trials by Phase 15
Clinical Trials by Trial Status 16
Subjects Recruited Over a Period of Time 17
Clinical Trials by Sponsor Type 18
Prominent Sponsors 19
Top Companies Participating in Cutaneous Mastocytosis Therapeutics Clinical Trials 20
Prominent Drugs 21
Clinical Trial Profiles 22
Clinical Trial Overview of Top Companies 22
AB Science 22
Clinical Trial Overview of AB Science 22
Novartis AG 23
Clinical Trial Overview of Novartis AG 23
JADO Technologies GmbH 24
Clinical Trial Overview of JADO Technologies GmbH 24
Clinical Trial Overview of Top Institutes / Government 25
The National Institute of Allergy and Infectious Diseases 25
Clinical Trial Overview of The National Institute of Allergy and Infectious Diseases 25
Charite - Universitatsmedizin Berlin 26
Clinical Trial Overview of Charite - Universitatsmedizin Berlin 26
Five Key Clinical Profiles 27
Appendix 65
Abbreviations 65
Definitions 65
Research Methodology 66
Secondary Research 66
About GlobalData 67
Contact Us 67
Disclaimer 67
Source 68

List of Tables
Cutaneous Mastocytosis Therapeutics, Global, Clinical Trials by Region, 2014* 5
Cutaneous Mastocytosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 6
Cutaneous Mastocytosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 7
Cutaneous Mastocytosis Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 8
Cutaneous Mastocytosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 9
Cutaneous Mastocytosis Therapeutics Clinical Trials, North America, Top Countries, 2014* 10
Proportion of Cutaneous Mastocytosis to Dermatology Clinical Trials, G7 Countries (%), 2014* 11
Cutaneous Mastocytosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 12
Cutaneous Mastocytosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 13
Cutaneous Mastocytosis Therapeutics, Global, Clinical Trials by Phase, 2014* 14
Cutaneous Mastocytosis Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 15
Cutaneous Mastocytosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 16
Cutaneous Mastocytosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 17
Cutaneous Mastocytosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 18
Cutaneous Mastocytosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 19
Cutaneous Mastocytosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 20
Cutaneous Mastocytosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 21
Cutaneous Mastocytosis Therapeutics Clinical Trials Market, Global, Clinical Trials by AB Science, 2014* 22
Cutaneous Mastocytosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 23
Cutaneous Mastocytosis Therapeutics Clinical Trials Market, Global, Clinical Trials by JADO Technologies GmbH, 2014* 24
Cutaneous Mastocytosis Therapeutics Clinical Trials Market, Global, Clinical Trials by The National Institute of Allergy and Infectious Diseases, 2014* 25
Cutaneous Mastocytosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Charite - Universitatsmedizin Berlin, 2014* 26

List of Figures
Cutaneous Mastocytosis Therapeutics, Global, Clinical Trials by Region (%), 2014* 5
Cutaneous Mastocytosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 6
Cutaneous Mastocytosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 7
Cutaneous Mastocytosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 9
Proportion of Cutaneous Mastocytosis to Dermatology Clinical Trials, G7 Countries (%), 2014* 11
Cutaneous Mastocytosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 12
Cutaneous Mastocytosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 13
Cutaneous Mastocytosis Therapeutics, Global, Clinical Trials by Phase (%), 2014* 14
Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 15
Cutaneous Mastocytosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 16
Cutaneous Mastocytosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 17
Cutaneous Mastocytosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 18
Cutaneous Mastocytosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 19
Cutaneous Mastocytosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 20
Cutaneous Mastocytosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 21
GlobalData Methodology 66

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.